checkAd

     812  0 Kommentare Sobi exercises opt-in right for Elocta(TM) - Seite 3

    For more information please contact
    Sobi
    Media Contact:                                       
    Charlotte af Klercker                               
    T: +46 70 7 297 327                      
    charlotte.afklercker@sobi.com              

    Investor Relations contact:
    Jörgen Winroth
    T: +1 347-224-0819, +1 212-579-0506
    jorgen.winroth@sobi.com




    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

    Lesen Sie auch

    HUG#1873208
    Seite 3 von 3




    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Sobi exercises opt-in right for Elocta(TM) - Seite 3 Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Elocta (rFVIIIFc) for the territory composed of Europe, North …